-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Spero Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2023.
- Spero Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$19.1M, a 47.9% decline year-over-year.
- Spero Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was $15.6M.
- Spero Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $21.5M.
- Spero Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$42.2M, a 52% increase from 2021.
- Spero Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$88M, a 11.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)